Impact of Tocilizumab on the Mortality of Patients With Coronavirus Disease 2019.
作者信息
Huang Yu-Tien, Chao Chien-Ming, Lai Chih-Cheng
机构信息
Department of Internal Medicine, Chi Mei Medical Center, Liouying, Tainan, Taiwan.
Department of Intensive Care Medicine, Chi Mei Medical Center, Liouying, Tainan, Taiwan.
出版信息
Clin Infect Dis. 2021 Jun 15;72(12):e1156-e1157. doi: 10.1093/cid/ciaa1738.
Abstract
摘要
相似文献
1
Impact of Tocilizumab on the Mortality of Patients With Coronavirus Disease 2019.托珠单抗对2019冠状病毒病患者死亡率的影响。
Clin Infect Dis. 2021 Jun 15;72(12):e1156-e1157. doi: 10.1093/cid/ciaa1738.
2
Benign SARS-CoV-2 infection in MOG-antibodies associated disorder during tocilizumab treatment.托珠单抗治疗期间伴 MOG 抗体相关疾病的良性 SARS-CoV-2 感染。
Mult Scler Relat Disord. 2020 Nov;46:102592. doi: 10.1016/j.msard.2020.102592. Epub 2020 Oct 21.
3
Tocilizumab; A Potential Remedy Against The Ever-Evolving Threat Of Coronavirus-2 (SARS-Cov-2).托珠单抗：应对不断演变的新型冠状病毒2（SARS-CoV-2）威胁的一种潜在疗法。
J Pak Med Assoc. 2023 Aug;73(8):1776-1777. doi: 10.47391/JPMA.8551.
4
Outcome Heterogeneity in Coronavirus Disease 2019 (COVID-19) Patients Receiving Tocilizumab.接受托珠单抗治疗的2019冠状病毒病（COVID-19）患者的结局异质性
Clin Infect Dis. 2022 Apr 28;74(8):1504. doi: 10.1093/cid/ciab816.
5
Impact of Timing of Tocilizumab Use in Hospitalized Patients With SARS-CoV-2 Infection.托珠单抗使用时机对住院的2019冠状病毒病感染患者的影响
Respir Care. 2022 May;67(5):629-630. doi: 10.4187/respcare.10067.
6
Tocilizumab for reduction of mortality in severe COVID-19 patients: How should we GRADE it?托珠单抗降低重症 COVID-19 患者死亡率：我们应如何对其进行分级？
Br J Clin Pharmacol. 2022 Jul;88(7):3539-3541. doi: 10.1111/bcp.15283. Epub 2022 Mar 2.
7
Tocilizumab prescribing criteria for COVID-19 patients.COVID-19患者的托珠单抗处方标准。
Hum Vaccin Immunother. 2021 Apr 3;17(4):1128. doi: 10.1080/21645515.2020.1822137. Epub 2020 Oct 20.
8
Tocilizumab for hospitalized patients with COVID-19.托珠单抗用于住院的新冠肺炎患者。
CMAJ. 2021 Apr 12;193(15):E521. doi: 10.1503/cmaj.210066. Epub 2021 Mar 9.
9
Testing the efficacy of tocilizumab in patients with COVID-19 pneumonia.测试托珠单抗对新冠肺炎肺炎患者的疗效。
J Comp Eff Res. 2021 Jun;10(8):625-627. doi: 10.2217/cer-2021-0050. Epub 2021 Apr 23.
10
Tocilizumab: From Rheumatic Diseases to COVID-19.托珠单抗：从风湿性疾病到 COVID-19。
Curr Pharm Des. 2021;27(13):1597-1607. doi: 10.2174/1381612827666210311141512.
引用本文的文献
1
Systematic Review and Subgroup Meta-analysis of Randomized Trials to Determine Tocilizumab's Place in COVID-19 Pneumonia.确定托珠单抗在新冠病毒肺炎治疗中地位的随机试验系统评价和亚组荟萃分析
Infect Dis Ther. 2021 Sep;10(3):1195-1213. doi: 10.1007/s40121-021-00488-6. Epub 2021 Jul 11.
2
Tocilizumab reduces the risk of ICU admission and mortality in patients with SARS-CoV-2 infection.托珠单抗降低了 SARS-CoV-2 感染患者 ICU 入院和死亡的风险。
Rev Esp Quimioter. 2021 Jun;34(3):238-244. doi: 10.37201/req/037.2021. Epub 2021 Apr 7.
Zotero 插件